Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

Snapshot
Detailed Quote
Advanced Chart &
Technical Analysis
News & Events
Compare
Analyst Opinions
Research Reports
Key Statistics
Earnings
Dividends
Ownership & Insiders
Financial Statements
SEC Filings

RELATED RESOURCES

Stock Research Overview
Stock Screeners
Markets & Sectors
Fidelity Learning Center

Print Format

Change Text Size:

Default text sizeA
Larger text sizeA
Largest text sizeA

BRIEF-FDA Approves XBiotech's IND In Rheumatology

BY Reuters
— 8:13 AM ET 12/13/2021

Dec 13 (Reuters) - XBiotech Inc (XBIT):

* FDA APPROVES XBIOTECH'S IND IN RHEUMATOLOGY

* XBIOTECH INC (XBIT) - FDA'S DIVISION OF RHEUMATOLOGY HAS AUTHORIZED CO TO COMMENCE CLINICAL DEVELOPMENT OF NATRUNIX Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More XBIT News

FDA Approves XBiotech’s IND in Rheumatology
GlobeNewswire - 8:00 AM ET 12/13/2021